# Plan de cuenta de EssilorLuxottica

> EssilorLuxottica fabrica y vende lentes, monturas, gafas inteligentes y tecnología ocular: 28.491 M€ de ingresos en 2025 y más de 200.000 empleados.

## De un vistazo

EssilorLuxottica es un grupo verticalmente integrado de salud visual y óptica, formado en 2018 a partir de Essilor (lentes) y Luxottica (monturas y distribución), que diseña, fabrica y vende lentes, monturas, gafas de sol, gafas inteligentes y, cada vez más, tecnología médica. Atiende a más de 300.000 clientes mayoristas y opera 17.750 tiendas a finales de 2025 en más de 150 países, con marcas como Ray-Ban, Oakley, Varilux, Transitions y licencias como Prada y Chanel. Los ingresos del ejercicio 2025 fueron de 28.491 M€, un 11,2 % más a tipos de cambio constantes, con un beneficio operativo ajustado de 4.459 M€ (15,7 % de los ingresos) y un beneficio neto atribuible de 2.315 M€. El grupo tiene más de 200.000 empleados. Cotiza en Euronext París (CAC 40, Euro Stoxx 50), y su matriz es Delfin, la holding de la familia Del Vecchio, con el 32,4 % del capital.

## Unidades de negocio

- **Professional Solutions (venta mayorista)** (48 % de los ingresos de 2025 (13.600 M€)): Suministra lentes, monturas, instrumentos, lentes de contacto y servicios a más de 300.000 clientes, desde ópticas independientes y cadenas hasta distribuidores, grandes almacenes y, ahora, oftalmólogos y hospitales. Los ingresos crecieron un 12,2 % a tipos de cambio constantes en 2025, con Norteamérica por encima del 40 % en el T4 gracias a las gafas con IA; el crecimiento se frenó al 4,9 % en el T2 de 2026.
- **Direct to Consumer (retail y comercio electrónico)** (52 % de los ingresos de 2025 (14.891 M€)): Gestiona enseñas como Sunglass Hut, LensCrafters, Vision Express, Pearle y GrandVision, sitios de comercio electrónico como Ray-Ban.com, el negocio de salud visual gestionada EyeMed con 85 millones de afiliados y casi 90 clínicas oftalmológicas en seis mercados europeos. Las ventas en tiendas comparables subieron un 7 % en 2025 y un 7,5 % en el S1 de 2026; el número de tiendas llegó a 19.686 a 30 de junio de 2026 tras la operación de Top Charoen.
- **Gafas inteligentes y dispositivos vestibles**: Las gafas con IA Ray-Ban Meta, Oakley Meta y Meta Ray-Ban Display con Meta, además de las gafas auditivas Nuance Audio lanzadas en 12 mercados y 15.000 tiendas. Fue el principal motor del S2 de 2025, y los ingresos de las gafas con IA casi se duplicaron en el T2 de 2026.
- **Tecnologías médicas y clínicas**: Una nueva plataforma medtech construida con Heidelberg Engineering (imagen OCT), RetinAI, Cellview Imaging, Espansione y las clínicas Optegra y Signifeye, con el objetivo de un recorrido del paciente integral, desde el cribado hasta el diagnóstico, la terapia y la cirugía.

## Prioridades estratégicas

- **Transformación medtech**: El grupo evoluciona «de un líder óptico “tradicional” a una empresa medtech, científica y basada en datos», con la construcción de clínicas, diagnóstico y software de cuidado ocular con IA.
- **Gafas con IA junto a Meta**: Extender las gafas con IA al estilo de vida, el deporte y la salud; la capacidad de producción de gafas inteligentes iba a ampliarse hasta 10 millones de unidades al año a finales de 2025, y en junio de 2026 se lanzó una colección Meta Glasses de 299 $.
- **Control de la miopía**: Llevar la plataforma Stellest hacia la prevención: Stellest obtuvo la autorización De Novo de la FDA en septiembre de 2025 y se lanzó en EE. UU. en el T4 de 2025; la cartera de miopía creció un 24 % en el T2 de 2026.
- **Organización nativa de IA**: Previsión de la demanda, copilotos para el personal de tienda y preparación para el comercio agéntico a partir de 2026, bajo una política de uso responsable de la IA.
- **Perspectivas a cinco años**: En los próximos cinco años, de media y a tipos de cambio constantes, un «crecimiento sólido» de los ingresos totales con un crecimiento del beneficio operativo ajustado en línea en términos generales.

## Últimos resultados

En el S1 de 2026 los ingresos fueron de 14.818 M€, un 9,7 % más a tipos de cambio constantes, con un +8,7 % en el T2 tras un +10,8 % en el T1 «en un entorno macroeconómico más inestable». El beneficio operativo ajustado subió un 15,0 % a tipos de cambio constantes, hasta 2.751 M€, un margen del 18,6 %, favorecido por la mejor rentabilidad de los dispositivos vestibles y un efecto neto positivo de los aranceles tras declarar el Tribunal Supremo de EE. UU. ilegales los aranceles adicionales de 2025. Direct to Consumer (8.001 M€, +11,4 %) superó a Professional Solutions (6.817 M€, +7,8 %), y Asia-Pacífico creció más rápido, con un +13,4 %. La deuda neta subió a 13,39 Md€ (2,0 veces el EBITDA) tras dividendos, recompras de acciones y adquisiciones. Las perspectivas a cinco años no cambiaron.

## Inversiones y operaciones

- **Adquisiciones medtech y de clínicas**: Las operaciones de 2025 incluyeron Optegra (más de 70 hospitales y clínicas oftalmológicas, cerrada el 1 de octubre de 2025), RetinAI, Cellview Imaging, Espansione y Pulse Audition; Signifeye se cerró en febrero de 2026. Las inversiones financieras netas de caja fueron de 911 M€ en 2025.
- **Expansión del retail en Asia y EE. UU.**: Una participación en Top Charoen, la mayor cadena óptica de Tailandia con casi 2.000 tiendas, se cerró el 2 de abril de 2026, y Pearle Vision adquirió West Point Optical Group (90 centros) en junio de 2026.
- **Capex y capacidad de dispositivos vestibles**: El capex fue de 1.525 M€ (5,4 % de los ingresos) en 2025; se amplió la capacidad de dispositivos vestibles en Dongguan, y la planta de Agordo, en Italia, albergará las primeras líneas de producción de dispositivos vestibles a partir de principios de 2027.
- **Alianza con Applied Materials**: Un acuerdo de desarrollo conjunto a largo plazo firmado en junio de 2026 abarca guías de onda, lentes adaptativas y óptica de realidad aumentada, con un laboratorio de colaboración en Silicon Valley.
- **Recompras de acciones**: Un programa de recompra de hasta 5.000.000 de acciones comenzó el 13 de febrero de 2026; en el S1 de 2026 se gastaron 969 M€ en 4.561.701 acciones.

## Retos y riesgos

- **Aranceles y dilución del margen**: Los aranceles de EE. UU. desde el T2 de 2025 y el mix de dispositivos vestibles redujeron el margen bruto ajustado al 60,9 % en 2025, desde el 63,5 % de 2024.
- **Competencia de las grandes tecnológicas en gafas inteligentes**: El URD (documento de registro universal) cita la entrada de las grandes tecnológicas en las gafas inteligentes como uno de los principales riesgos; Reuters informó de que la acción había perdido más de un 40 % desde su máximo de noviembre por la preocupación de los inversores ante la competencia.
- **Legitimidad en medtech**: El URD afirma que el grupo todavía no tiene en medtech la misma experiencia y legitimidad que en su negocio principal.
- **Ciberseguridad y privacidad de datos**: La ciberseguridad, los sistemas informáticos y la privacidad de datos figuran entre los riesgos más graves para un grupo que atiende a más de quinientos millones de pacientes y consumidores al año.
- **Geopolítica y aumento de la deuda**: Las tensiones en Oriente Medio pesaron sobre el negocio mayorista de EMEA en el T2 de 2026, China continental supone el 4 % de los ingresos, y la deuda neta subió a 13,39 Md€ en el S1 de 2026.

## Lo que dice la dirección

> "Our goal is to replace, by simplifying its functions, the current smartphone." — Francesco Milleri, Chairman and CEO, Entrevista en Il Foglio, 2025-04-15

> "We were too big to stay confined to this small market" — Francesco Milleri, Chairman and CEO, Declaraciones en la junta general recogidas por Reuters, 2026-04-28

> "A few big players have made product announcements that generated a lot of interest, but we have not yet seen real competing products on the market." — Francesco Milleri, Chairman and CEO, Declaraciones en la junta general recogidas por Reuters, 2026-04-28

> "Only a collaborative model, a network company, can keep leadership in innovation and technology." — Francesco Milleri, Chairman and CEO, Bloomberg Línea, 2025-10-10


## Dónde puede ayudar un proveedor

- **Software clínico y diagnóstico**: Vinculado a la transformación medtech y a la brecha de legitimidad reconocida en ese ámbito: los sistemas clínicos, la imagen, el diagnóstico con IA y la experiencia regulatoria ayudan a desarrollar la red de clínicas.
- **Componentes y fabricación de dispositivos vestibles**: Vinculado a la prioridad de las gafas con IA y a la inversión en capacidad de dispositivos vestibles: los proveedores de óptica, pantallas, chips, baterías y ensamblaje abastecen las nuevas líneas de Dongguan y Agordo.
- **IA para el retail y comercio agéntico**: Vinculado a la prioridad de la organización nativa de IA: previsión de la demanda, copilotos para el personal de tienda y herramientas de comercio agéntico en 19.686 tiendas y en el comercio electrónico.
- **Ciberseguridad y privacidad de datos**: Vinculado al reto de la ciberseguridad y la privacidad, que crece a medida que las clínicas y las gafas conectadas suman datos de salud y datos personales.
- **Apoyo a la integración de retail y clínicas adquiridos**: Vinculado a las adquisiciones de Top Charoen, West Point Optical y de clínicas: integración posterior a la fusión de sistemas informáticos, sistemas de tienda y procesos.

_Lectura de Tamtam de las prioridades y los retos anteriores, no palabras de la propia empresa._

## Documentos clave

### [2025 Universal Registration Document](https://www.essilorluxottica.com/caas/v1/media/284322/data/f95ef2e9903624401eeb5d083d1061bc/essilorluxottica-urd-en-2025-mel-march06.pdf)

Informe anual · 2026-03-06

- EssilorLuxottica (Paris-listed, CAC 40 and Euro Stoxx 50; parent company Delfin S.à r.l., Chairman and CEO Francesco Milleri, Deputy CEO Paul du Saillant) is the vertically integrated world leader in vision care, eyewear, smart eyewear and, increasingly, medical technology: 200,000+ employees, 150+ countries, ~18,000 stores (17,750 at end-2025), 150+ brands, 16,500+ patents and designs, 47 mass-production plants (33 lens, 14 frame), 555 prescription labs, 300,000+ wholesale customers, more than half a billion patients and consumers served every year.
- FY2025 revenue €28,491m, +11.2% at constant exchange rates (+7.5% reported), the first double-digit annual growth in the Group's history, with a record Q4 at +18.4%. Adjusted operating profit €4,459m (15.7% of revenue, 16.0% at constant FX, -70bps dilution from US tariffs and the mix of wearables), adjusted net profit €3,157m (+7.2% at constant FX), free cash flow €2,796m (+€383m), net debt €10,853m (1.7x EBITDA). Reported operating profit €3,379m (11.9%), net profit attributable €2,315m.
- Two operating segments: Professional Solutions (wholesale) €13,600m (+12.2% at constant FX) and Direct to Consumer (retail + e-commerce) €14,891m (+10.3%, comparable-store sales +7%, e-commerce up high-teens). By region: North America €12,787m (+11.6%), EMEA €10,779m (+11.8%, first time above €10bn), Asia-Pacific €3,410m (+10.1%), Latin America €1,515m (+7.6%).
- Growth engines: AI glasses with Meta (Ray-Ban Meta Gen 2, Oakley Meta HSTN and Vanguard, Meta Ray-Ban Display with in-lens display at $799), the dominant driver of H2 2025, with North America Professional Solutions up more than 40% in Q4; myopia management (Essilor Stellest, first FDA-authorised myopia-control spectacle lens, Stellest 2.0 in China, Nikon/Kodak DOT lenses worn by over one million children); Nuance Audio hearing glasses (FDA-cleared, 12 markets, 15,000 stores); lens premiumisation (Varilux, Transitions, Crizal, Eyezen, Shamir).
- Strategy rests on three pillars: med-tech, wearables/AI and the brand portfolio. 2025 M&A built a med-tech platform: Optegra (70+ eye hospitals and clinics in the UK, Czech Republic, Poland, Slovakia, Netherlands, closed 1 Oct 2025), Signifeye (15 Belgian clinics, closed Feb 2026), RetinAI (AI eye-care software), Cellview Imaging, Espansione, Pulse Audition, plus vertical-integration deals (PUcore monomers, Automation & Robotics, A-Look retail in Malaysia). Financial investments net of cash €911m; capex €1,525m (5.4% of revenue).
- New long-term outlook: over the next five years, on average and at constant exchange rates, "solid growth" of total revenue with broadly aligned growth of adjusted operating profit. Dividend proposed for 2025: €4.00 per share (approved April 2026). A new share buyback of up to 5,000,000 shares started 13 February 2026.
- Risks rated highest: cybersecurity/IT, data privacy, political and social environment (US tariffs, Middle East, China at 4% of revenue), competition from big tech in smart eyewear, and the Group's lesser legitimacy in med-tech; gross margin fell to 60.9% adjusted (63.5% in 2024) on tariffs and wearables mix.
- Executives' framing: the Group is evolving "from a 'traditional' optical leader into a med-tech, science and data-driven company", with smart eyewear expected "to redefine personal and wearable computing" and the eye as a window into systemic health (oculomics). A Scientific Advisory Committee of five scientists (Aspect, Figalli, Sahel, Kujawa, Vayena) was created in December 2025.

### [Q2/H1 2026 results press release and First-half 2026 Management Report](https://www.essilorluxottica.com/caas/v1/media/305620/data/94b0317fbbbad9529870391c3799ceea/essilorluxottica-q2h1-2026-press-release-en.pdf)

Informe intermedio · 2026-07-28

- H1 2026 revenue €14,818m, +9.7% at constant exchange rates (+5.7% reported), Q2 €7,692m at +8.7% after +10.8% in Q1, "in a more unsettled macro environment"; all regions and both segments grew.
- Adjusted operating profit €2,751m, +15.0% at constant FX, margin 18.6% (18.9% at constant FX, +80bps); adjusted gross margin 63.5% (+10bps) helped by better wearables profitability and a net positive tariff impact after the US Supreme Court ruled the 2025 additional tariffs unlawful in February 2026; adjusted net profit €1,921m (+13.3%); reported operating profit €2,296m, net profit attributable €1,566m, EPS €3.40 (€3.04).
- Direct to Consumer €8,001m (+11.4%, comparable-store sales +7.5% in H1, +8% in Q2) outpaced Professional Solutions €6,817m (+7.8%, +4.9% in Q2, low-single-digit in North America, EMEA and Latin America, mid-teens in Asia-Pacific).
- Regions H1: North America €6,374m (+9.9%), EMEA €5,785m (+8.7%, Middle East tensions weighed on Q2 wholesale), Asia-Pacific €1,853m (+13.4%, Q2 +17.0% with China, India, Japan and Korea at double digits and Top Charoen consolidated), Latin America €806m (+6.7%).
- Product engines: core eyecare/eyewear mid-single digit; myopia portfolio +24% in Q2 (Stellest ramp-up in the US, Stellest 2.0 and Nikon/Kodak DOT in China); AI glasses "almost doubling" in Q2 revenue, rolled out to Singapore, Japan and South Korea, with Ray-Ban Meta Optics prescription styles (from $499) and the $299 Meta Glasses collection launched in June.
- Free cash flow €1.07bn (€0.96bn), but net debt rose to €13.39bn (2.0x EBITDA LTM of €6,821m) after €1.73bn of dividends (only 9% took shares vs 70% in 2025), €969m of buybacks (4,561,701 shares at €211.51 average) and acquisitions; cash €1.93bn.
- Store count jumped to 19,686 (17,750 at end-2025) with Top Charoen in Thailand (almost 2,000 stores, stake closed 2 April 2026); other deals: Signifeye (Feb 2026), Faro CNC machinery (April), West Point Optical (90 Pearle Vision centres, June); licence with Dolce&Gabbana extended to 2050.
- Strategic moves: long-term joint development agreement with Applied Materials (June 2026) on waveguides, adaptive lenses and AR optics with a lab in Silicon Valley; first wearables production lines in Italy at Agordo from early 2027; a Responsible Use of AI policy.
- Outlook unchanged: over the next five years, solid revenue growth and broadly aligned adjusted operating profit growth at constant exchange rates; Q3 2026 revenue due 20 October 2026.

### [Il Foglio: "Possible innovations and challenges for Italy" - a conversation with Francesco Milleri](https://www.ilfoglio.it/economia/2025/04/15/news/possible-innovations-and-challenges-for-italy-a-conversation-with-francesco-milleri-ceo-of-essilorluxottica--113962)

Intervención de un directivo · Francesco Milleri, Chairman and Chief Executive Officer · 2025-04-15

- Wide-ranging interview (Il Foglio, Claudio Cerasa, 15 April 2025; English AI translation) with Francesco Milleri, 66 covering smart glasses, med-tech, chips, data ethics, Italy and Delfin's financial stakes.
- Core bet: "in the digital society, sight and hearing are destined to take on an increasingly central role"; the eye is "the only organ in our body exposed to the outside, easily monitorable", so glasses will unify vision, hearing and voice. Stated goal: "to replace, by simplifying its functions, the current smartphone."
- Smart glasses could carry biometric authentication (iris, jawbone vibration), a payment wallet, car and home controls; Nuance Audio shows optics converging with audiology, and he expects applications in automotive, sports, agriculture, medicine and the space economy.
- Display technology is the real breakthrough to come: research focuses on microLEDs, waveguides, holography and metasurfaces; lamination will embed invisible circuits in lenses; low-power eye-tracking will turn the eye into "a true 'mouse'".
- Med-tech thesis: the eye can reveal Alzheimer's, Parkinson's, metabolic, cardiovascular and kidney conditions; acquisitions of Heidelberg Engineering, Espansione, Pulse Audition and Cellview move the Group "upstream along the entire chain"; surgical suites are being piloted in North American stores; "the longevity economy is destined to drive global trends".
- Silicon: the Group is "already filing patents for innovative low-power chips" and sees "a very profitable business" in custom optics controllers and sensor arrays.
- Data and ethics: the Group serves "over half a billion customers" a year and processes "billions of data points"; it is considering an ethical-scientific committee of international experts; the answer to fragmented privacy regulation is "collaborative rather than competitive models".
- Delfin (32.2% of EssilorLuxottica; stakes in Mediobanca 19.9%, Generali 9.8%, Unicredit 2.7%, MPS 9.78%): "purely financial investments" meant to bring technology and scale to Italian finance; he supports the MPS-Mediobanca operation as "a step to make the financial sector in our country more competitive".

### [Bloomberg Línea: EssilorLuxottica prepares to lead the AI-glasses market with Meta (Milleri on Bloomberg's "Quello che i soldi non dicono" podcast)](https://www.bloomberglinea.com/negocios/essilorluxottica-se-prepara-para-liderar-el-mercado-de-gafas-con-ia-junto-a-meta/)

Intervención de un directivo · Francesco Milleri, Chairman and Chief Executive Officer · 2025-10-10

- Bloomberg Línea article (10 October 2025, Spanish) reporting a rare interview Francesco Milleri gave to Bloomberg's Italian podcast "Quello che i soldi non dicono": he is positioning "the world's largest eyewear company" to lead AI glasses, which "could replace smartphones as the next consumer-tech hit".
- Capacity: EssilorLuxottica is expanding smart-glasses production capacity to 10 million units a year by the end of 2025, betting on rising demand; the capacity can also serve other smart glasses and Nuance Audio hearing glasses.
- Milleri: glasses, "for so long considered prostheses and later fashion accessories, are on the way to becoming the central device in people's lives, possibly replacing smartphones"; he foresees "hundreds of millions of interconnected smart glasses... creating immense communities".
- The Meta partnership generated an estimated €365m of revenue in 2024 and could approach €800m in 2025 and exceed €6bn in 2030 in Barclays' most optimistic projections; analysts see the category rising from ~3 million to 60 million units a year by 2035. Meta invested $3.5bn for about 3% of the capital; Zuckerberg unveiled the $799 Meta Ray-Ban Display in September.
- Strategy: use the integrated platform of labs, factories and stores to sell higher-value products (myopia-control lenses, med-tech used in clinical settings, wearables); "only a collaborative model, a network company, can keep leadership in innovation and technology"; investment in medical technology including clinical AI and "even beyond ophthalmology".
- Other points: Supreme acquired in 2024 to reach younger consumers; Armani described only as "a prospect for evolution"; competition from Chinese and US players and uncertain consumer uptake are flagged; market value about €128bn at the time; Milleri, 65, became chairman in 2022 and the market value has more than doubled since.

### [Reuters: EssilorLuxottica's CEO confident the share price will recover over time (remarks at the 28 April 2026 AGM)](https://www.boursorama.com/bourse/actualites/le-directeur-general-d-essilorluxottica-est-convaincu-que-le-cours-de-l-action-remontera-a-terme-96be49ea5c199c79b6e4f837df34790a)

Intervención de un directivo · Francesco Milleri, Chairman and Chief Executive Officer · 2026-04-28

- Reuters report (Elisa Anzolin, 28 April 2026, French machine translation on Boursorama) of Francesco Milleri's remarks at EssilorLuxottica's annual general meeting in Paris.
- Milleri said he is confident the shares will regain the ground lost to US tariffs, a weak dollar, spreading military conflicts and competition in smart glasses; the stock had lost more than 40% since its November record, which had been driven by enthusiasm for Ray-Ban Meta AI glasses.
- He acknowledged the shares also suffered from the continued push into medical technology, which he called a necessary transformation: "We were too big to stay confined to this small market," referring to traditional frames and lenses; once completed, the med-tech transformation "will bear fruit and support the recovery of the share price".
- On competition: "A few big players have made product announcements that generated a lot of interest, but we have not yet seen real competing products on the market."
- "We are really doing everything to regain the (price) position that is rightfully ours... but, at the same time, it will take some time to get there."
- Reuters recalls that EssilorLuxottica has worked with Meta Platforms since 2019 on successive generations of Ray-Ban glasses with cameras, audio and AI features.

### [The Moodie Davitt Report: Alessio Crivelli on blending eyewear craftsmanship with med-tech](https://moodiedavittreport.com/interview-essilorluxotticas-alessio-crivelli-on-blending-eyewear-craftsmanship-with-med-tech-innovation/)

Intervención de un directivo · Alessio Crivelli, Managing Director Global Travel Retail · 2025-10-31

- Interview (The Moodie Davitt Report, Hannah Tan, 31 October 2025) with Alessio Crivelli, EssilorLuxottica Managing Director Global Travel Retail and newly appointed TFWA Vice-President Marketing, at the TFWA World Exhibition in Cannes.
- "As our CEO Francesco Milleri often says, EssilorLuxottica is not just an eyewear company - we are a med-tech company"; licensed brands and fashion products "remain essential" and "drive desirability", but another side of the business is "deeply rooted in instruments and optical technology".
- Business split: "Roughly speaking, half of our business is direct-to-consumer, through retail and ecommerce, while the other half is what we call 'Professional Solutions', which serves opticians and wholesalers"; both cover optical and sun.
- The med-tech identity is "a natural progression" of the Essilor-Luxottica merger, which "our CEO envisioned... long before it happened"; integration "has not been easy, but today we're operating at full speed" and enables new categories such as AI eyewear.
- Cannes showcase: Oakley Meta, Nuance Audio, Persol, Prada, Miu Miu and Versace, and the world-first Ray-Ban Automated Retail Solution prototype, an autonomous 24/7 eyewear shopping unit for high-traffic travel environments.
- Travel retail: sunglasses are "underweighted compared to other luxury segments" and "deserve greater visibility and space"; the channel focuses on sun but is testing optical with an in-store lab delivering a complete prescription pair in 30 minutes, including for airport staff.
- Outlook: eyewear "has always been a resilient category" and "the future of affordable luxury in travel retail"; "people may not buy a handbag or a watch, but they'll treat themselves to a pair of sunglasses"; a multi-brand outpost opened with Tasa Meng at Taoyuan airport in May 2025.

### [La República: Ernesto Díaz, President of Professional Solutions for Hispanic America, on Ray-Ban Meta, Nuance Audio and Colombia](https://www.larepublica.co/empresas/ernesto-diaz-presidente-de-professional-solutions-essilorluxottica-hablo-de-las-ray-ban-meta-4128247)

Intervención de un directivo · Ernesto Díaz, President of Professional Solutions EssilorLuxottica for Hispanic America · 2025-05-08

- La República (Colombia, Martín Pinzón Lemos, 8 May 2025, Spanish) interview with Ernesto Díaz, President of Professional Solutions EssilorLuxottica for Hispanic America, at the opening of a new showroom in the company's Bogotá offices.
- Global revenue €26,508 million with 6% growth at constant rates (FY2024); Latin America grew 9.7%, and "we are growing at a double-digit pace in Latin America".
- After Brazil and Mexico, Colombia is the region's most important market, and "the Latin market where the professionalism of optometrists is highest... the reference at regional level".
- Customers: "a little more than 5,000 doors registered as customers in Colombia" and "between 30,000 and 40,000 formal customers in Latin America".
- Innovations planned for Colombia within two years: Ray-Ban Meta (Meta AI, voice commands, live translation into the ear, apps for the blind) and Nuance Audio open-ear hearing glasses for mild-to-moderate hearing loss; Bliz, a recent acquisition, was added to cover the sports segment at "quality at a reasonable price".
- Ambition: "We project that our business could double or even triple in a relatively short period of two to three years, and the showroom is a key tool to reach this goal."
- Country manager Felipe Laverde: the Colombian wholesale business serves the optical segment (ophthalmic lenses, frames and specialised instruments) and luxury fashion stores selling sunglasses.

## Preguntas sobre EssilorLuxottica

### ¿Qué hace EssilorLuxottica?

EssilorLuxottica diseña, fabrica y vende lentes graduadas, monturas, gafas de sol, lentes de contacto, gafas inteligentes e instrumentos de cuidado ocular, a través de la venta mayorista a ópticas y de sus propias tiendas y comercio electrónico. Está construyendo un negocio medtech con clínicas oftalmológicas y diagnóstico.

### ¿Cuáles fueron los ingresos de EssilorLuxottica en 2025?

Los ingresos del ejercicio 2025 fueron de 28.491 M€, un 11,2 % más a tipos de cambio constantes, el primer crecimiento anual de dos dígitos en la historia del grupo; el beneficio operativo ajustado fue de 4.459 M€.

### ¿Cuántos empleados tiene EssilorLuxottica?

El grupo tiene más de 200.000 empleados en más de 150 países.

### ¿Quién dirige EssilorLuxottica?

Francesco Milleri es presidente y consejero delegado, y Paul du Saillant es consejero delegado adjunto. Delfin, la holding de la familia Del Vecchio presidida por Milleri, es la sociedad matriz.

### ¿Cuál es la estrategia de EssilorLuxottica?

La estrategia se apoya en tres pilares: medtech, dispositivos vestibles e IA mediante las gafas inteligentes, y la cartera de marcas, con unas perspectivas a cinco años de crecimiento sólido de los ingresos a tipos de cambio constantes.

_Redactado por Tamtam a partir de los documentos publicados por la propia empresa, enumerados arriba y leídos íntegramente. Las cifras son las de esos documentos, para los periodos que indican. (2026-11-17)_
